methyl 2-[(tert-butoxycarbonyl)amino]-3,3-dimethylpent-4-enoate | 192330-57-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-[(tert-butoxycarbonyl)amino]-3,3-dimethylpent-4-enoate
• 英文别名: methyl 2(R/S)-(tert-butoxycarbonyl)amino-3,3-dimethyl-4-pentenoate；Methyl 2(r/s)-(tert-butoxycarbonyl)amino-3,3-dimethyl4-pentenoate；methyl 3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-enoate
• CAS: 192330-57-7
• 化学式: C₁₃H₂₃NO₄
• 分子量: 257.33
• InChiKey: CHCHFINYRQQFKK-UHFFFAOYSA-N

物化性质

• 沸点：
  324.6±35.0 °C(Predicted)
• 密度：
  1.011±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-[(tert-butoxycarbonyl)amino]-3,3-dimethylpent-4-enoate 在 Alcalase 作用下， 以 水 、 乙腈 为溶剂， 反应 51.0h， 以42%的产率得到2-((tert-butoxycarbonyl)amino)-3,3-dimethylpent-4-enoic acid
  参考文献：
  名称：

  生产（2 S）-4,4-二氟-3,3-二甲基-N -Boc-脯氨酸的高效酶促工艺，这是合成HIV蛋白酶抑制剂的关键中间体

  摘要：

  （2S）-4，4-二氟-3，3-二甲基-N -Boc-脯氨酸（3）是合成HIV蛋白酶抑制剂的关键中间体。在此，公开了制备对映体3及其类似物的几种方法。在这些方法中，一种策略依赖于通过蛋白酶催化的对映选择性水解来拆分3的外消旋甲酯。尽管采用了该分辨率来制备千克量的光学纯酸3对于临床试验，该方法效率低，成本高且难以通过中等工程技术改进。因此，通过将脯氨酸酯的保护基团从Boc转换为苄基部分，开发了另一种效率更高且更具成本效益的酶促工艺。该新方法的通量更高（6.3 mmol / h / L vs. 0.11 mmol / h / L），而且该方法的成本也大大降低至蛋白酶拆分过程的5％。

  DOI：

  10.1021/op060004+
• 作为产物：
  描述：

  methyl 2-[(benzyloxy)amino]-3,3-dimethylpent-4-enoate 在 molybdenum hexacarbonyl 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 2.5h， 生成 methyl 2-[(tert-butoxycarbonyl)amino]-3,3-dimethylpent-4-enoate
  参考文献：
  名称：

  Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability

  摘要：

  Previous reports from our laboratories described potent tripeptide thrombin inhibitors which incorporate heterocycle-substituted chlorophenyl groups in the PI position. Using these as lead compounds for further optimization, we identified sites of metabolism and designed analogs with 4-fluoroproline in P2 and cyclopropane-containing side chains in P3 as an approach to reducing metabolism and improving their oral pharmacokinetic performance. The large (300-fold) difference in potency between analogs containing (4R)- and (4S)-4-fluoroproline was rationalized by analyzing inhibitor-enzyme interactions in crystal structures of related compounds and by molecular modeling which indicated that the more potent (4R)-4-fluoroproline isomer stabilizes a proline ring conformation that is preferred for binding to the enzyme. An optimal compound from this work, 41, exhibits high potency in a coagulation assay in human plasma (2xAPTT = 190 nM), excellent selectivity versus the digestive enzyme trypsin (K-i = 3300 nM), and excellent oral bioavailability in dogs with moderate clearance (F = 100%, CL = 12 mL/min/kg). (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.06.040

文献信息

• Process Research and Development and Scale-up of a 4,4-Difluoro-3,3-dimethylproline Derivative
  作者：Francesco Rossi、Francesco Corcella、Francesco Saverio Caldarelli、Franco Heidempergher、Chiara Marchionni、Miriam Auguadro、Marco Cattaneo、Lucio Ceriani、Giuseppina Visentin、Giambattista Ventrella、Vittorio Pinciroli、Giuliano Ramella、Ilaria Candiani、Angelo Bedeschi、Attilio Tomasi、Billie J. Kline、Carlos A. Martinez、Daniel Yazbeck、David J. Kucera

  DOI：10.1021/op7001112

  日期：2008.3.1

  scaled up. Synthesis of the proline skeleton began with construction of racemic glycine derivative 4, via an ester enolate Claisen rearrangement of Boc-glycine 3-methyl-but-2-enyl ester ( 3) in the absence of a Lewis acid. After a classical resolution of 4 with ( S)-phenylglycinol, ( S)- 4 was transformed into bromo-lactone 6b with NBS. The bromo-lactone was transformed to proline alcohol 8 via a base-promoted

  HIV蛋白酶抑制剂的关键中间体脯氨酸衍生物1的多公斤级生产 需要设计一种能够安全，有效且易于扩大规模的合成途径。脯氨酸骨架的合成始于外消旋甘氨酸衍生物4的构建 ，是通过在不存在路易斯酸的情况下Boc-甘氨酸3-甲基-丁-2-烯基酯（3）的酯烯酸酯克莱森重排而进行的。在用（S）-苯基甘氨醇经典拆分 4后，用NBS将（S）-4转化为溴代内酯 6b。溴内酯转化为脯氨酸 8通过涉及内酯溶剂分解的碱基促进的重排。NMR研究表明，最初形成了双环内酯，随后被甲醇溶剂打开形成 8。氟化所需的酮是使用NaClO和催化TEMPO通过对映体纯的8的氧化制备的 。 然后，通过用Deoxo-Fluor氟化从酮制得宝石-二氟脯氨酸 1。在这项研究过程中，发现SiO 2促进了Deoxo-Fluor氟化作用。这项研究允许10步生产7.5公斤 1，摩尔产率为4.5％，纯度高（HPLC分析为94-99％）。
• [EN] HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES<br/>[FR] INHIBITEURS DE LA PROTEASE DU VIH, COMPOSITIONS LES CONTENANT ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：PFIZER

  公开号：WO2005026114A1

  公开（公告）日：2005-03-24

  This invention relates to a novel series of chemical compounds useful as Human immunodeficiency Virus (HIV) protease inhibitors and to the use of such compounds as antiviral agents. The invention further relates to pharmaceutical compositions containing such antiviral agents, and their uses and materials for their synthesis

  这项发明涉及一类新型化合物系列，可用作人类免疫缺陷病毒（HIV）蛋白酶抑制剂，以及将这些化合物用作抗病毒剂的用途。该发明还涉及含有这种抗病毒剂的药物组合物，以及它们的用途和合成材料。
• [EN] METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION<br/>[FR] INHIBITEURS DE METALLOPROTEINASES, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES INHIBITEURS ET LEURS UTILISATIONS PHARMACEUTIQUES, ET PROCEDES ET INTERMEDIAIRES SERVANT A LEUR PREPARATION
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：WO1997020824A1

  公开（公告）日：1997-06-12

  (EN) The invention relates to compounds of formula (1) wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.(FR) Cette invention se rapporte à des composés représentés par la formule (1), dans laquelle: Z représente O ou S; V représente un radical divalent qui, avec C* et N, forme un cycle ayant 6 atomes cycliques, où chacun de ces atomes cycliques autres que C* et N indépendamment est insubstitué ou substitué par un substituant approprié, et au moins l'un de ces autres atomes cycliques est un hétéroatome choisi parmi O, N et S, et les atomes restants sont des atomes de carbone; et Ar représente un groupe aryle ou hétéroaryle. Cette invention se rapporte en outre à des promédicaments, des sels et des solvates de ces composés, qui sont acceptables sur le plan pharmaceutique. Cette invention se rapporte également à des procédés pour inhiber l'activité de métalloprotéinases, en administrant un composé représenté par la formule (1) ou un promédicament, sel ou solvate de ce composé. Cette invention se rapporte en outre à des compositions pharmaceutiques comprenant une quantité efficace de ces composés, promédicaments, sels et solvates. Cette invention se rapporte enfin à des procédés et à des intermédiaires servant à préparer ces composés, promédicaments, sels, et solvates.

  本发明涉及式（1）的化合物，其中：Z为O或S；V为二价基团，与C*和N一起形成一个具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代物取代，且其中至少一个其他环原子是从O、N和S中选择的杂原子，其余为碳原子；Ar为芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化物。本发明还涉及这些化合物的药学上可接受的前药、盐和溶剂化物。本发明还涉及通过给予式（1）的化合物或其前药、盐或溶剂化物来抑制金属蛋白酶活性的方法。本发明还涉及包含这些化合物、前药、盐和溶剂化物的有效量的药物组合物。本发明还涉及用于制备这些化合物、前药、盐和溶剂化物的有用方法和中间体。
• Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US20030130506A1

  公开（公告）日：2003-07-10

  The invention relates to compounds of the formula 1: 1 wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  本发明涉及式1:1的化合物，其中：Z为O或S；V是一个二价基团，与C*和N一起形成具有六个环原子的环，其中除C*和N之外的每个环原子独立地未取代或被适当取代基团取代，且其中至少一个其他环原子是从O、N和S中选择的杂原子，其余是碳原子；Ar是芳基或杂芳基；以及其药学上可接受的前药、盐和溶剂化物。本发明还涉及这些化合物的药学上可接受的前药、盐和溶剂化物。本发明还涉及通过给予式I或其前药、盐或溶剂化物来抑制金属蛋白酶活性的方法。本发明还涉及包含这些化合物、前药、盐和溶剂化物的有效量的制药组合物。本发明还涉及用于制备这些化合物、前药、盐和溶剂化物的有用方法和中间体。
• Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06500948B1

  公开（公告）日：2002-12-31

  The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

  本发明涉及化合物的公式1：其中：Z为O或S; V为二价基团，与C*和N一起形成具有六个环原子的环，其中，除了C*和N之外的每个环原子独立地未取代或被适当取代基团取代，而且至少一个其他环原子是从O、N和S中选择的杂原子，其余为碳原子; Ar为芳基或杂芳基基团;以及其药学上可接受的前药、盐和溶剂化物。本发明还涉及这些化合物的药学上可接受的前药、盐和溶剂化物。本发明还涉及通过给予公式I或其前药、盐或溶剂化物来抑制金属蛋白酶活性的方法。本发明还涉及包含这些化合物、前药、盐和溶剂化物的有效量的制药组合物。本发明还涉及用于制备这些化合物、前药、盐和溶剂化物的有用方法和中间体。